Cargando…
Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461995/ https://www.ncbi.nlm.nih.gov/pubmed/34556168 http://dx.doi.org/10.1186/s13045-021-01154-7 |
| _version_ | 1784572105281503232 |
|---|---|
| author | Wang, Chunmeng Shi, Fengxia Liu, Yang Zhang, Yajing Dong, Liang Li, Xiang Tong, Chuan Wang, Yao Su, Liping Nie, Jing Han, Weidong |
| author_facet | Wang, Chunmeng Shi, Fengxia Liu, Yang Zhang, Yajing Dong, Liang Li, Xiang Tong, Chuan Wang, Yao Su, Liping Nie, Jing Han, Weidong |
| author_sort | Wang, Chunmeng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8461995 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84619952021-09-24 Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy Wang, Chunmeng Shi, Fengxia Liu, Yang Zhang, Yajing Dong, Liang Li, Xiang Tong, Chuan Wang, Yao Su, Liping Nie, Jing Han, Weidong J Hematol Oncol Correction BioMed Central 2021-09-23 /pmc/articles/PMC8461995/ /pubmed/34556168 http://dx.doi.org/10.1186/s13045-021-01154-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Wang, Chunmeng Shi, Fengxia Liu, Yang Zhang, Yajing Dong, Liang Li, Xiang Tong, Chuan Wang, Yao Su, Liping Nie, Jing Han, Weidong Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title | Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title_full | Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title_fullStr | Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title_full_unstemmed | Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title_short | Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| title_sort | correction to: anti-pd-1 antibodies as a salvage therapy for patients with diffuse large b cell lymphoma who progressed/relapsed after cart19/20 therapy |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461995/ https://www.ncbi.nlm.nih.gov/pubmed/34556168 http://dx.doi.org/10.1186/s13045-021-01154-7 |
| work_keys_str_mv | AT wangchunmeng correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT shifengxia correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT liuyang correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT zhangyajing correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT dongliang correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT lixiang correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT tongchuan correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT wangyao correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT suliping correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT niejing correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy AT hanweidong correctiontoantipd1antibodiesasasalvagetherapyforpatientswithdiffuselargebcelllymphomawhoprogressedrelapsedaftercart1920therapy |